LKS Advises SAI Parenterals on Cross‑Border Acquisition of Noumed Pharmaceuticals

"Lakshmikumaran & Sridharan advised Sai Parenterals Limited and its Singapore subsidiary Sai Parenterals Pte Limited on the cross‑border acquisition of a 74.6% stake in Noumed Pharmaceuticals Pty Ltd (Australia). The deal combined a secondary purchase from Noumed Life Sciences Ltd (UK) with a primary subscription by way of a convertible loan."

Lakshmikumaran & Sridharan Attorneys advised and acted for Sai Parenterals Limited and its Singapore subsidiary, Sai Parenterals Pte Limited, in connection with the transaction. The transaction involved Sai Parenterals acquiring a 74.6% equity stake in Noumed Pharmaceuticals Pty Ltd, an Australian company. The acquisition was effected through a combination of a secondary purchase of shares from Noumed Life Sciences Limited (United Kingdom) and a primary subscription by way of a convertible loan. Lakshmikumaran & Sridharan Attorneys provided comprehensive end-to-end legal support across all stages of the transaction, including drafting, review, negotiation and finalisation of a suite of complex transaction documents. The firm coordinated and managed the closing process and liaised with multiple stakeholders across jurisdictions to facilitate a seamless completion. Lakshmikumaran & Sridharan Attorneys represented Sai Parenterals Limited and Sai Parenterals Pte Limited with a team composed by: Noorul Hassan (Executive Partner), Shipra Verma (Associate Partner) and Alekhya Kanda (Senior Associate).

LKS Advises SAI Parenterals on Cross‑Border Acquisition of Noumed Pharmaceuticals

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads